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The incidence and mortality of lung cancer have been increasing
in Japan and lung cancer is the leading cause of cancer death. An
attempt to reduce lung cancer mortality is an issue of great impor-
tance. Because cigarette smoking is the predominant cause, lung
cancer is mainly preventable. However, anti-smoking activities
need a latent period before a substantial reduction of mortality
becomes apparent. Since long-term smokers remain at high risk
for prolonged periods even after quitting, effective secondary
prevention measures are also important. 
In Japan since 1987 local governments have been obligated to
offer an annual screening programme for lung cancer using chest
X-ray and/or sputum cytology, to residents aged 40 or over, under
the Health and Medical Services Law for the Aged. However, so
far there is insufficient evidence to confirm its efficacy in terms of
reducing mortality. It is necessary to assess whether this screening
programme is effective or not from the standpoint of public health
policies. 
A randomized controlled trial is the best approach to evaluate
efficacy of the screening. Although several randomized trials in
the United States and in Europe have been conducted to evaluate
lung cancer screening, none of them showed any evidence of
benefit in terms of mortality reduction (Fontana et al, 1986;
Tockman, 1986; Melamed and Flehinger, 1987; Kubik et al, 1990).
In Japan, a randomized controlled trial would be difficult to
conduct, because annual chest X-ray screening is already wide-
spread under the Tuberculosis Control Law since the 1950s. 
The case–control study is an alternative approach to examine
the efficacy of screening. Although there are several potential
biases (Hosek et al, 1996; Cronin et al, 1998), this approach can be
applied in situations where a screening test has been widespread in
the general public before its efficacy has been determined by
clinical trials. 
In this paper, we reported the results of a case–control study
evaluating lung cancer screening in Niigata Prefecture, Japan. 
SUBJECTS AND METHODS 
Study setting 
In Niigata Prefecture, Japan, screening for lung cancer using chest
X-ray and sputum cytology has been performed since 1985. The
records of screening participants, i.e., name, date of birth, address
and results of screening test, are stored in each municipality. From
1990 to 1997, a total of 243 785 people participated in the
screening, and 1721 cases of lung cancer were detected. After
screening by chest X-ray and/or sputum cytology, 1.0–2.8% of all
participants were referred to hospitals for diagnostic and thera-
peutic procedures every year, and 95–100% of referred people
actually visited hospitals (Yokoyama, 1999). In 12 municipalities
of this study area from 1995 to 1998, the rate of clinical stage I
disease for cases detected by screening was 76%, and was 24% for
symptomatic cases. In addition, the 5-year survival rates were 51%
and 15%, respectively (Tsukada et al, 2000). 
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Source population 
The study areas consisted of 17 municipalities of relatively small
populations (the populations aged 40 or over were less than 
15 000), mostly in rural areas where the populations of middle-
aged or elderly people were stable. Data during 1990–1997 in 14
municipalities and 1992–1997 in 3 municipalities were collected
and examined in this study. We defined the source population as
National Health Insurance holders in the study area, aged 40 or
over (47 117 people). All were invited to lung cancer screening
annually under the Health and Medical Services Law for the Aged. 
Screening 
Both chest X-ray for all participants and sputum cytology for high-
risk group were used for screening. Chest X-rays were taken by
miniature photofluorography with 140 kv, using 100 × 100 mm
film. Saccomanno’s 3-day pooled method was used for sputum
cytology. The high-risk group for sputum cytology was defined as
those who ranked 400 or more on the smoking index (average
number of cigarettes smoked per day multiplied by the number of
years smoked). Those who were suspected of having lung cancer
were referred to hospitals. 
Identification of cases 
In 1990–97, all deaths due to lung cancer in the source populations
were identified by death certificates and/or through the Niigata
Cancer Registry. Case subjects were defined as the people who (1)
had been National Health Insurance holders, (2) had died of lung
cancer between the ages of 40 and 79, (3) had been diagnosed
during the study period, (4) had lived in the same area since the
beginning of the study period. 
In order to increase the efficiency of identifying controls
matched by smoking habits, cases were limited to the high-risk
group for males and the non-high-risk group for females, because
of the high smoking prevalence in males and low smoking preva-
lence in females in Japan. 
Information at diagnosis was collected from the medical records
of the hospitals where the case subjects were diagnosed as lung
cancer. Clinical stage was determined according to UICC staging
system (UICC, 1992). Migration status was investigated from
records of residence obtained from local governments. Inform-
ation on smoking habits for the cases were obtained from medical
records, screening records and interview surveys. When there
were discrepancies in information, priority was given to the higher
smoking index. 
A total of 580 deaths due to lung cancer were identified in the
source population during the study period. Of these, 162 cases
were excluded because they had been either over 79 years old or
under 40 years old at the time of death. In 7 cases, through the
review of medical records, their deaths turned out to be due to
other causes. 129 cases were found to have been non-National
Health Insurance holders and 26 cases had been diagnosed as
having lung cancer before the study period. In addition, 22 cases
were excluded because they had moved into the municipality
during the study period. 15 cases in males were excluded because
they were classified in the non-high-risk group and 9 female 
cases in the high-risk group. Smoking habits of 6 cases could not
be determined. In 24 other cases, the date of diagnosis could not be
identified, because of destruction or loss of medical records (3
cases) or physician’s refusal (3 cases). As a result, a total of 180
cases were collected. 
For cases covered by the above process, an additional interview
survey was conducted with the families to investigate not only
smoking habits, but also some confounding factors, namely, (i)
frequency of health check-ups other than the lung cancer screening
and (ii) routine consultations at local medical facilities, both of
which appeared to be associated with the opportunities of exami-
nation by chest X-ray. Well-trained public health nurses who
belonged to local health centres or local governments conducted
these interviews, and they visited the houses of cases or phoned
and used a uniform questionnaire. 
Identification of controls 
For each case an attempt was made to select 10 controls from the
list of National Health Insurance holders at the beginning of the
study period. In 9 municipalities, the list at the beginning was not
available, and the list was reconstructed from the oldest available
list and the file of death certificates before the list was made. In
each study area, all cases were identified in the list. To ensure that
case and control subjects had equal access to screening during the
exposure period, control candidates were selected from those
located near the case, matched by sex and year of birth (±2 years).
In addition, controls were required to have been alive and National
Health Insurance holders at the time when the corresponding case
was diagnosed. As a result, 1770 control candidates were selected. 
Controls were interviewed, using the same questionnaire as
cases, by visiting and/or telephone in 16 areas and mail alone in
one area. If deceased, a family member was interviewed if
possible. The smoking index for controls was calculated using the
years smoked up to the time when the corresponding case was
diagnosed. Interviews were continued until 5 appropriate controls
(high-risk males or non-high-risk females) were obtained. 
During these processes, 413 control candidates were excluded
because they were classified either in the non-high-risk group for
males or in the high-risk group for females. 44 control candidates
were excluded because of migration into the area after the diag-
nosis of the matched case. In addition, 101 controls were excluded
because getting information from them was impossible due to
death, emigration, or refusal. In one town, the questionnaires of
excluded controls were discarded immediately, and the reason why
21 candidates were excluded was unclear. 
In total, 825 controls were selected from 1770 control candidates. 
Identification of screening history 
Screening histories of both cases and controls were obtained from
the lists of screened people kept at local government offices or local
health centres. Screening histories of cases and matched controls
were reviewed within the same calendar period before the case was
diagnosed as lung cancer. Controls were not counted as screened if
this occurred after the diagnosis of the ‘case’ lung cancer. In some
municipalities, screening records of decedants are destroyed after
an interval. Since the screening records of 6 cases within 12 months
before diagnosis had been erased, these 6 cases and 24 matched
controls were excluded. The records of the 12 controls which had
been destroyed (though the corresponding case records were avail-
able) were regarded as unscreened in the relevant 12 months in
order not to overestimate the efficacy of screening. 
Since it was impossible to check for the existence of symptoms,
we considered those who participated in a screening programme as1328 H Tsukada et al
British Journal of Cancer (2001) 85(9), 1326–1331 © 2001 Cancer Research Campaign
having an actual screening test, that is, a test that leads to a diag-
nosis in the absence of symptoms. 
Finally, 174 cases and 801 controls were used for the analysis. 
Analyses 
The odds ratio of dying from lung cancer for screened vs non-
screened people and 95% confidence interval (CI) were calculated
using conditional logistic regression analysis with PHREG
Procedure in the SAS computer program. Smoking-adjusted odds
ratios were calculated by including 8 dichotomous variables on the
smoking index (200 to 399, 400 to 599, 600 to 799, 800 to 999, 1000
to 1199, 1200 to 1399, 1400 to 1599 and 1600 or more) in the model.
Screening histories were categorized as dichotomous whether the
study subjects had been screened or not within the 0–12 and 12–24
months before the case was diagnosed as lung cancer. 
Information about other health check-ups and the frequency of
routine medical consultation were obtained from the interview
surveys for 152 cases and 678 controls. In order to estimate the
confounding effects, these variables were included in the model,
according to the methods described by Sobue et al (1992). 
Sub-group analyses of the odds ratios according to sex, age,
histologic type of tumour were also performed with conditional
logistic regression model, holding each matched set. 
RESULTS 
The characteristics of deceased cases are shown in Table 1. Out of
174 cases, 159 cases (91.4%) were diagnosed with histological
and/or cytological evidence of lung cancer, while the remaining 15
cases were diagnosed by chest X-ray and/or clinical findings
alone. The predominant histologic type for females was adeno-
carcinoma, whereas squamous cell carcinoma and small cell carci-
noma were the major types in male cases. Over two thirds of the
cases of both sexes had stage III or stage IV cancers at diagnosis. 
Table 2 shows the distribution by smoking index at diagnosis 
for cases and controls. Although smoking status was matched
(smoking index ≥ 400), male cases had significantly higher
smoking indexes than controls (P = 0.001). 
Table 3 shows the odds ratios of dying from lung cancer among
individuals with screening histories as compared with those not
screened. The smoking adjusted odds ratio of dying from lung
cancer for those who were screened within 12 months compared
with those not screened was 0.401 (95% CI: 0.272–0.591). We
also calculated the odds ratio of dying from lung cancer for those
who were screened during 12 to 24 months compared with those
not screened (excluding those screened within 12 months). The
odds ratio was 1.418 and 95% CI was 0.634–3.173, suggesting that
no reduction in risk exists over 1 year after a negative screening
result (Table 3). 
Table 4 shows the odds ratios when the 2 variables, which might
be associated with chest X-ray examination outside the screening
programme, were added to the model. Analyses were limited to
152 cases and 678 controls, for which information on these vari-
ables was available; the non-exposed group was used as the refer-
ence group. Health check ups other than lung cancer screening and
routine medical consultations are not associated with reduced
mortality for lung cancer. Adjustment for these two variables
scarcely alters the association with lung cancer screening. 
Table 5 shows the odds ratios according to age, sex and histo-
logic type. A statistically significant reduction of the risk for lung
cancer death was observed for all ages in males. Odds ratios were
lower in males than in females although the 95% CIs overlapped.
Table 1 Characteristics of the cases 
Males Females 
n % n % 
Age
40–49 4 2.7 1 4.0 
50–59 7 4.7 4 16.0 
60–69 65 43.6 6 24.0 
70–75 51 34.2 8 32.0 
76–79 22 14.8 6 24.0 
Histologic type
Squamous cell carcinoma 47 31.5 1 4.0 
Adenocarcinoma 57 38.2 19 76.0 
Small cell carcinoma 32 21.5 1 4.0 
Large cell carcinoma 1 0.7 1 4.0 
Unknown 12 8.1 3 12.0 
Clinical stage
I 18 12.1 2 8.0 
II 5 3.3 1 4.0 
IIIA 27 18.1 0 0.0 
IIIB 31 20.8 10 40.0 
IV 61 40.9 11 44.0 
Unknown 7 4.7 1 4.0 
Total 149 100.0 25 100.0 
Table 2 Smoking index of cases and controls 
Males Females 
Smoking index Cases Controls Cases Controls 
n % n % n % n % 
0 0 0.0 0 0.0 22 88.0 119 98.3 
1–399 0 0.0 0 0.0 3 12.0 2 1.7 
400–599 11 7.4 160 23.5 0 0.0 0 0.0 
600–799 13 8.7 146 21.5 0 0.0 0 0.0 
800–1199 78 52.3 256 37.6 0 0.0 0 0.0 
1200–1399 9 6.0 27 4.0 0 0.0 0 0.0 
1400–1599 8 5.4 31 4.5 0 0.0 0 0.0 
1600+ 30 20.1 60 8.8 0 0.0 0 0.0 
Total 149 100.0 680 100.0 25 100.0 121 100.0 Evaluation of lung cancer screening  1329
British Journal of Cancer (2001) 85(9), 1326–1331 © 2001 Cancer Research Campaign
The odds ratio for squamous cell carcinoma was lower than that
for adenocarcinoma although the reduction of the risk for lung
cancer death was significant in both. 
DISCUSSION 
In this case–control study, an approximately 60% reduction of the
risk for lung cancer death was observed for those who were
screened within 12 months before the diagnosis of lung cancer,
compared with those unscreened. 
In a previous case–control study in Japan (Sobue et al, 1992),
the odds ratio of dying from lung cancer for those screened (in
1981–88) vs non-screened was 0.72 (95% CI: 0.50–1.03). The
odds ratio in our study (evaluating screening in 1990–1997) was
0.401 (95% CI: 0.272–0.591), which was statistically significant
in spite of smaller sample size than the former study. 
Table 3 Odds ratios of dying from lung cancer for those screened vs. unscreened according to the period for comparing
screening histories before diagnosis of the case 
Months Number of Number of Smoking-adjusted 
before subjects availablea subjects screened (%)b odds ratioc
diagnosis Cases Controls Cases Controls (95% Confidence interval) 
0–12 174 801 61 (35.0) 450 (56.2) 0.40 (0.27–0.59) 
12–24d 85 205 14 (16.5) 29 (14.1) 1.42 (0.63–3.17) 
aThe number of subjects who had the chance to participate in screening during the period. bSubjects who were screened in
the period/ number of subjects (%) cCalculated for previous screening history 0–12 and 12–24 months before case
diagnosis, compared with no screening history in those intervals, using conditional logistic regression analysis. dCases and
controls who had been screened within 12 months before diagnosis were excluded. Cases and controls who had no
matched subjects were also excluded. 
Table 4 Odds ratios of dying from lung cancer for those screened within 12 months before diagnosis in
which variables associated with the chest X-ray examination were includeda
Variables Exposure (%) Smoking-adjusted odds ratio 
Cases Controls (95% confidence interval) 
Lung-cancer screeningb 35 57 0.420 (0.276–0.64) 
Other health check-upsc 28 29 0.855 (0.55–1.33) 
Routine medical consultationd 66 55 1.492 (0.997–2.23) 
aAnalyses were limited to 152 cases and 678 controls for which information on additional variables were
available. bAttendance at screening offered by local government within 12 months. cAttendance at any kind of
health check-up except the above screening at least annually. dRoutine consultations at least every 3 months
for any reason. 
Table 5 Odds ratios of dying from lung cancer for those screened within 12 months before diagnosis by sex, age and
histologic type 
Number of Screened (%) Smoking-adjusted odds ratio 
Cases Controls Cases Controls (95% confidence interval) 
Sex/Age
Male
40–69 87 398 34.5 57.0 0.367 (0.209–0.645) 
70–79 62 282 33.9 56.7 0.405 (0.207–0.792) 
Total 149 680 34.2 56.9 0.373 (0.245–0.569) 
Female
40–69 12 61 66.7 65.6 1.101 (0.248–4.885) 
70–79 13 60 15.4 38.3 0.319 (0.065–1.560) 
Total 25 121 40.0 52.1 0.614 (0.225–1.675) 
Histologic type
Squamous 48 220 27.1 55.0 0.212 (0.088–0.510) 
Adeno 76 347 34.2 55.3 0.431 (0.240–0.773) 
Small 33 160 45.5 58.8 0.592 (0.248–1.410) 
Unknown 15 67 40.0 56.7 0.506 (0.147–1.749) 
Squamous: squamous cell carcinoma; Adeno: adenocarcinoma; Small: small cell carcinoma. 1330 H Tsukada et al
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During the 1980s, there was a technological advance in minia-
ture fluorography and an improvement in quality control of
screening system. At present, a 100 × 100 mm photofluorograph
taken with a mirror camera, 140 kV X-ray beam and a rare earth-
intensifying fluorescent screen are used in lung cancer screening.
Two physicians, whose specialty is respiratory diseases, indepen-
dently interpret the X-ray findings and compare the films with
previous ones when any abnormalities are found. This current
standard screening system became widespread in the late 1980s. 
From 1995 to 1998, in 12 municipalities included in this study
area, stage I diseases were detected on population-based screening
3 times as frequently as by symptoms (Tsukada et al, 2000), which
suggests a higher proportion of curable cancers compared with
those detected by other means. In fact, it has to be noted that the 5-
year survival rate for lung cancer patients detected by screening
between 1990 and 1997 was 48.1% in Niigata Prefecture
(Yokoyama, 1999), which is quite different from the findings in a
case–control study conducted in East Berlin that showed no bene-
ficial evidence of lung cancer screening. The 5-year survival rate
for asymptomatic lung cancer patients in the East Berlin Study was
reported as 6.8% (Ebeling et al, 1987). 
However, our study has several methodological problems. 
(1) Although some investigators recommend only screening
done in the absence of symptoms should be counted (Cole
and Morrison, 1980; Cronin et al, 1998), case subjects in this
study were not investigated as to whether they were
symptom-derived screenees or not. The symptom-derived
screening visits among the case subjects may have led to a
substantial underestimation of screening efficacy. 
(2) Although we tried to reduce the influence of smoking habits
in controlling for self-selection bias, we did not take other
confounding factors into consideration, such as environ-
mental exposure and vegetable intake. The possibility that a
more healthy lifestyle among controls could lead to over-
estimation of screening efficacy cannot be ruled out. 
(3) Information on the variables associated with the chances of
chest X-ray outside the lung cancer screening was obtained
differently from cases (family member only interviewed) and
controls themselves interviewed. Furthermore, the question-
naire asked if they routinely consulted a doctor or not, or if
they received health check-ups other than the lung cancer
screening. These variables did not imply that they had actu-
ally had chest X-rays. Confounding could arise if lung cancer
cases more commonly had chest X-ray for co-morbid
disease, such as emphysema. For some of the cases, the back-
ground disease for routine medical consultation had been
hypertension or diabetes, so that the chances of chest X-ray
might not have been high. The data in Table 4 must therefore
be interpreted with caution. 
(4) 26 cases diagnosed before 1990 were excluded in the present
study. To restrict cases to persons diagnosed with cancer
during a given period of time and fail to include these 26
cases may produce a falsely low odds ratio and, thus, an
overestimation of the efficacy of screening (Weiss and
Lazovich, 1996). However, it is probable that the extent of
bias from this source would be small because the excluded
cases comprise only a relatively small fraction of the total
cases. 
(5) We had to exclude 30 case candidates. If the attendance rate
for screening of these 30 case candidates (6 excluded due to
unidentified smoking habits, 24 to unidentified date of
diagnosis) was higher than that of 178 adopted cases, the
efficacy of the screening might be overestimated. Since the
date of diagnosis was unclear, attendance rate within 12
months before diagnosis was unable to be determined.
However, screening histories between 1990 and the date of
death were able to be identified in 23 of 30 case candidates,
and only 6 of the 23 (26.1%) had been screened during the
period. The attendance rate of the 23 case candidates within
12 months before diagnosis was no more than 26.1%, and the
rate was lower than that of 178 adopted cases (35.0%).
Accordingly, overestimation of efficacy caused by exclusion
of these cases was considered to be minimum in this study. 
(6) The reasons why 21 control candidates were excluded were
unclear. However, 10 of 21 (47.6%) candidates were
screened within 12 months before the corresponding case
was diagnosed, and the attendance rate was higher than that
of the cases (35.0%). The odds ratio would not be changed
much even if 21 candidates were not excluded. 
(7) 101 non-respondent controls were excluded from the
analysis, which might cause some bias. In order to assess 
the possible bias, an additional analysis was performed using
the screening histories of 73 of these 101 non-respondents
(the other 28 non-respondents could not be obtained). Of
these 73 controls, attendance rate within 12 months before
diagnosis was only 16.5%, which was lower than that of
cases (35.0%), so that their exclusion might overestimate the
efficacy of the screening. The odds ratio was then calculated
including these 73 candidates both with and without
smoking-adjustment (assigning smoking index to the median
of adopted controls; 830 for males and 0 for females). The
odds ratio without smoking-adjustment was 0.419 (95% CI:
0.290–0.606), and with smoking-adjustment 0.436 (95% CI:
0.297–0.642). The change of the odds ratio was therefore
relatively small. 
To define the appropriate screening interval, screening histories
were categorized whether subjects had been screened or not in the
0–12 and 12–24 months before the diagnosis of the cases.
Excluding those screened within 12 months the odds ratio for
those screened during 12–24 months was calculated as 1.418 and
thus, no reduced risk was shown. Since the duration of detectable
pre-clinical phase associated with chest X-ray examination is rela-
tively short, lung cancer does not seem as suitable for mass-
screening as uterine cervical cancer (Clarke and Anderson, 1979)
and colorectal cancer (Faivre et al, 1999) for which screening once
every 2 years appears to be efficacious. 
In the present study, a significant protective effect of screening
on mortality was not observed for females unlike the previous
study in Japan (Sobue et al, 1992). It should be noted that the
odds ratio for squamous cell carcinoma tended to be lower than
that for adenocarcinoma, although the 95% CIs overlapped. The
greater effect in males than females and also in squamous cell
carcinoma than adenocarcinoma may imply that an appreciable
effect might be derived more from sputum cytology than from
chest X-ray in our screening programme. In the present study,
any screening visit was counted as ‘screened’, regardless of the
examination (X-ray + sputum/X-ray only), so that an indepen-
dent effect of sputum cytology could not be evaluated and further
studies are required. 
Recently, the low-radiation-dose computed tomography (CT)
has been shown to greatly increase the likelihood of detection of
smaller, probably earlier, lung cancers than do chest X raysEvaluation of lung cancer screening  1331
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(Henschke et al, 1999). Our findings may point towards evaluating
the efficacy of CT screening for lung cancer. 
In our study, the odds ratio of dying from lung cancer for 
those screened within 12 months of case diagnosis vs those not
screened was 0.401 (95% CI 0.272–0.591), but we could not avoid
self-selection bias. Since it has probably overestimated the effi-
cacy of the screening, the findings cannot refute the conclusions of
large-scale randomized trials conducted in the 1970s and 1980s.
However, our results suggest that, with the current standard unique
method in Japan using miniature fluorography with independent
double interpretation under good quality control, significant
mortality reduction from lung cancer could be expected. 
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